PROK (ProKidney) 3-Year Sharpe Ratio : N/A (As of Jul. 09, 2025)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-09), ProKidney's 3-Year Sharpe Ratio is Not available.

Competitive Comparison of ProKidney's 3-Year Sharpe Ratio

For the Biotechnology subindustry, ProKidney's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProKidney's 3-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where ProKidney's 3-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

ProKidney 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.

ProKidney (NAS:PROK) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

ProKidney 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of ProKidney's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » 3-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

PROK:Mexico

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Executives

Control Empresarial De Capitales S.a. De C.v.	10 percent owner	INSURGENTES SUR #3500, PB, COL. PENA POBRE, DELEGACION TLALPAN, CP, MEXICO D.F. O5 14060
Darin J. Weber	officer: SVP of Regulatory Development	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Pablo G. Legorreta	director, 10 percent owner	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Chamath Palihapitiya	10 percent owner	THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc	10 percent owner	506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc	10 percent owner	506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton	officer: EVP, Clinical Development	2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen	10 percent owner	540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger	officer: Chief People Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle	director
Tolerantia, Llc	10 percent owner	110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio	director	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain	officer: Chief Operating Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie	officer: Chief Medical Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston	officer: Chief Financial Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103